Rapport Therapeutics, Inc.(RAPP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RAPP Rapport Therapeutics, Inc.

已收盘 02-13 16:00:00 EST

27.93

-0.04

-0.14%

盘后28.00

+0.07+0.25%

16:10 EST

最高29.17	最低26.41	成交量40.08万
今开27.85	昨收27.97	日振幅9.87%
总市值13.31亿	流通市值7.42亿	总股本4,766万
成交额1,138万	换手率1.51%	流通股本2,657万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":27.93,"timestamp":1771016400000,"preClose":27.97,"halted":0,"volume":400785,"hourTrading":{"tag":"盘后","latestPrice":28,"preClose":27.93,"latestTime":"16:10 EST","volume":4075,"amount":113821.75,"timestamp":1771017004898,"change":0.07,"changeRate":0.002506,"amplitude":0.002506},"delay":0,"changeRate":-0.001430103682516952,"floatShares":26567199,"shares":47661138,"eps":-2.716762,"marketStatus":"已收盘","change":-0.04,"latestTime":"02-13 16:00:00 EST","open":27.85,"high":29.17,"low":26.41,"amount":11380340.57391,"amplitude":0.098677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.716762,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":5,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":27.97,"preHourTrading":{"tag":"盘前","latestPrice":27.97,"preClose":27.97,"latestTime":"08:10 EST","volume":4,"amount":111.88,"timestamp":1770988224669,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":28,"preClose":27.93,"latestTime":"16:10 EST","volume":4075,"amount":113821.75,"timestamp":1771017004898,"change":0.07,"changeRate":0.002506,"amplitude":0.002506},"volumeRatio":1.605011,"impliedVol":0.7493,"impliedVolPercentile":0.3865},"requestUrl":"/m/hq/s/RAPP/wiki","defaultTab":"wiki","newsList":[{"id":"1131033553","title":"Rapport Therapeutics计划于2027年上半年启动RAP-219治疗PGTCs的三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1131033553","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131033553?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:08","pubTimestamp":1767787738,"startTime":"0","endTime":"0","summary":"生物制药公司Rapport Therapeutics, Inc.近日披露重要研发进展，宣布将于2027年上半年正式启动其核心候选药物RAP-219针对原发性全身性强直阵挛发作的三期临床试验。这一关键性临床阶段的启动，标志着该药物在癫痫治疗领域的开发迈入决定性阶段。业界关注到，RAP-219作为一种创新疗法，其临床进展对满足PGTCs患者的未竟医疗需求具有重要意义。此次三期试验的启动计划，不仅体现了Rapport Therapeutics在神经科学领域的研发实力，也可能为癫痫治疗格局带来新的变革。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"1117807206","title":"Rapport Therapeutics：Rap-219 第二阶段临床试验进展顺利，预计2027年上半年公布主要结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1117807206","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117807206?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:22","pubTimestamp":1762431766,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics：Rap-219 第二阶段临床试验进展顺利，预计2027年上半年公布主要结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2566988061","title":"美股周三早盘专注于中枢神经系统（CNS）疾病创新疗法研发的生物制药公司Rapport Therapeutics股价重挫此","url":"https://stock-news.laohu8.com/highlight/detail?id=2566988061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566988061?lang=zh_cn&edition=full","pubTime":"2025-09-10 23:46","pubTimestamp":1757519183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4135","BK4139","RAPP","LENZ","CNS","BK4007"],"gpt_icon":0},{"id":"2566600190","title":"生物制药公司Rapport重挫18.8%，此前完成2.5亿美元的公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=2566600190","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566600190?lang=zh_cn&edition=full","pubTime":"2025-09-10 22:54","pubTimestamp":1757516040,"startTime":"0","endTime":"0","summary":"美股周三早盘，专注于中枢神经系统（CNS）疾病创新疗法研发的生物制药公司Rapport Therapeutics（RAPP）股价重挫18.8%，此前该公司以每股26美元的价格完成2.5亿美元的公开发行。\n　　此次发行预计将于2025年9月11日完成，所筹资金将用于支持公司的增长计划。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-10/doc-infpzray3944272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CNS","RAPP","BK4007","BK4135"],"gpt_icon":0},{"id":"1160286321","title":"Rapport Therapeutics Inc.按每股26.00美元价格公开发行960万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1160286321","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160286321?lang=zh_cn&edition=full","pubTime":"2025-09-10 09:19","pubTimestamp":1757467151,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc.宣布以每股26.00美元的价格公开发行960万股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"1127369274","title":"异动解读 | 癫痫药物临床试验成功，Rapport Therapeutics盘前大涨171.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127369274","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127369274?lang=zh_cn&edition=full","pubTime":"2025-09-08 18:46","pubTimestamp":1757328398,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc.今日盘前股价大涨171.59%，引发市场广泛关注。这一显著涨幅主要源于该公司宣布其实验性癫痫药物RAP-219在中期临床试验中取得积极结果。根据公司公布的数据，RAP-219在针对难以治疗的局灶性癫痫发作成人患者的2a期临床试验中表现出色。Rapport Therapeutics表示，计划在2025年第四季度与美国食品药品监督管理局举行2期试验结束会议，并有意在2026年第三季度启动两项后期研究。考虑到该公司此前年内股价累计下跌19.5%，这次利好消息无疑为投资者注入了新的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RAPP"],"gpt_icon":1},{"id":"1191517947","title":"Rapport Therapeutics公布局灶性癫痫发作试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1191517947","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191517947?lang=zh_cn&edition=full","pubTime":"2025-09-08 18:42","pubTimestamp":1757328127,"startTime":"0","endTime":"0","summary":"9月8日 - Rapport Therapeutics Inc.宣布其RAP-219药物在局灶性癫痫发作患者中的2A期临床试验取得积极的顶线结果。\n试验达到主要终点，RAP-219耐受性良好。\n患者癫痫发作减少77.8%，24%的患者实现无癫痫发作状态。\nRAP-219耐受性良好，不良事件轻微。\n公司计划在2025年第四季度与美国食品药品监督管理局(FDA)举行2期试验结束会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"1173937408","title":"Rapport Therapeutics, Inc.公布Rap-219治疗局灶性癫痫发作患者2a期临床试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1173937408","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173937408?lang=zh_cn&edition=full","pubTime":"2025-09-08 18:00","pubTimestamp":1757325627,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc.宣布其药物Rap-219在治疗局灶性癫痫发作患者的2a期临床试验中取得积极的顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"1118444204","title":"Rapport Therapeutics将于2025年9月8日周一公布Rap-219治疗局灶性癫痫发作2a期临床试验的初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1118444204","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118444204?lang=zh_cn&edition=full","pubTime":"2025-09-06 04:06","pubTimestamp":1757102776,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics将于2025年9月8日周一公布Rap-219治疗局灶性癫痫发作2a期临床试验的初步数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"1126656451","title":"Rapport Therapeutics 2024财年第四季度每股亏损$(0.57)，优于预期$(0.62)，年末现金、现金等价物和短期投资达3.053亿美元，预计可支持运营至2026年底","url":"https://stock-news.laohu8.com/highlight/detail?id=1126656451","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126656451?lang=zh_cn&edition=full","pubTime":"2025-03-11 19:43","pubTimestamp":1741693381,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics 报告季度每股亏损$，优于分析师预期的$，超出8.06%。与去年同期每股亏损$相比，这是一个92.88%的增长。以上内容来自Benzinga Earnings专栏，原文如下：Rapport $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 8.06 percent. This is a 92.88 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","RAPP"],"gpt_icon":0},{"id":"2518274695","title":"Rapport Therapeutics, Inc.盘中异动 股价大跌5.24%报8.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518274695?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:00","pubTimestamp":1741615239,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时00分，Rapport Therapeutics, Inc.股票出现波动，股价急速下跌5.24%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3087.26%、661.78%、287.22%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为41.36%、40.24%、28.59%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220039abf3078d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220039abf3078d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","RAPP","LENZ","BK4139"],"gpt_icon":0},{"id":"2517163165","title":"Rapport Therapeutics, Inc.盘中异动 快速跳水5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517163165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517163165?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:31","pubTimestamp":1741271504,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时31分，Rapport Therapeutics, Inc.股票出现波动，股价快速下挫5.54%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.63%。其相关个股中，Plus Therapeutics, Inc.、Exicure, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为946.46%、104.14%、48.84%，振幅较大的相关个股有Plus Therapeutics, Inc.、Entero Therapeutics Inc.、Astria Therapeutics, Inc.，振幅分别为24.20%、13.05%、11.88%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223145abeb7784&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223145abeb7784&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","RAPP","BK4139","LENZ"],"gpt_icon":0},{"id":"2516340206","title":"Rapport Therapeutics, Inc.盘中异动 快速跳水5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516340206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516340206?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012315,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Rapport Therapeutics, Inc.股票出现异动，股价急速跳水5.78%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.17%、23.41%、22.45%，振幅较大的相关个股有Entero Therapeutics Inc.、Cibus, Inc.、Galmed Pharmaceuticals Ltd.，振幅分别为11.70%、9.55%、9.35%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032231559637ac09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032231559637ac09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LENZ","RAPP"],"gpt_icon":0},{"id":"2516937063","title":"Rapport Therapeutics, Inc.盘中异动 快速跳水5.03%报10.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516937063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516937063?lang=zh_cn&edition=full","pubTime":"2025-03-01 02:06","pubTimestamp":1740765996,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日02时06分，Rapport Therapeutics, Inc.股票出现波动，股价急速下挫5.03%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.05%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301020636a2583559&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301020636a2583559&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RAPP","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2514862502","title":"Rapport Therapeutics, Inc.盘中异动 股价大跌5.09%报11.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862502","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514862502?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:13","pubTimestamp":1740600826,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时13分，Rapport Therapeutics, Inc.股票出现波动，股价急速跳水5.09%。截至发稿，该股报11.18美元/股，成交量21.0055万股，换手率0.57%，振幅8.32%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.66%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270413469893e853&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270413469893e853&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RAPP","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2514003019","title":"Rapport Therapeutics, Inc.盘中异动 快速下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514003019","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514003019?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:23","pubTimestamp":1740500639,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时23分，Rapport Therapeutics, Inc.股票出现异动，股价快速下挫5.06%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1331.76%、1114.37%、902.45%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为224.93%、87.83%、66.67%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260023599892645f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260023599892645f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RAPP","BK4007","LENZ"],"gpt_icon":0},{"id":"2514708900","title":"Rapport Therapeutics, Inc.盘中异动 急速拉升5.52%报13.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514708900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514708900?lang=zh_cn&edition=full","pubTime":"2025-02-25 03:54","pubTimestamp":1740426886,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日03时54分，Rapport Therapeutics, Inc.股票出现波动，股价快速拉升5.52%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.17%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为324.89%、139.35%、40.20%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、162.04%、81.92%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225035446989134fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225035446989134fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RAPP","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2512353514","title":"Rapport Therapeutics, Inc.盘中异动 下午盘大幅下跌5.13%报13.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512353514","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512353514?lang=zh_cn&edition=full","pubTime":"2025-02-20 02:57","pubTimestamp":1739991465,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日02时57分，Rapport Therapeutics, Inc.股票出现波动，股价急速下跌5.13%。截至发稿，该股报13.32美元/股，成交量4.4918万股，换手率0.12%，振幅8.90%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.53%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220025745abd52e7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220025745abd52e7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RAPP","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2512169270","title":"Rapport Therapeutics, Inc.盘中异动 股价大跌5.03%报15.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512169270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512169270?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:17","pubTimestamp":1739891876,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时17分，Rapport Therapeutics, Inc.股票出现波动，股价急速下挫5.03%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。其相关个股中，Allogene Therapeutics, Inc.、Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为353.35%、135.13%、128.47%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Allogene Therapeutics, Inc.，振幅分别为148.75%、51.40%、50.49%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182317569627a049&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182317569627a049&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4139","RAPP"],"gpt_icon":0},{"id":"2511691391","title":"Rapport Therapeutics, Inc.盘中异动 股价大涨5.23%报16.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511691391","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511691391?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:55","pubTimestamp":1739544901,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时55分，Rapport Therapeutics, Inc.股票出现异动，股价大幅上涨5.23%。Rapport Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Moleculin Biotech, Inc.、Virpax Pharmaceuticals, Inc.、Cns Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为2034.72%、525.34%、439.22%，振幅较大的相关个股有Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Klotho Neurosciences, Inc.，振幅分别为66.93%、40.35%、33.28%。Rapport Therapeutics, Inc.公司简介：Rapport Therapeutics Inc 是一家临床阶段的生物制药公司，专注于为中枢神经系统疾病患者发现和开发转化性小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214225501962320e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214225501962320e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","RAPP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rapportrx.com","stockEarnings":[{"period":"1week","weight":0.0947},{"period":"1month","weight":0.0321},{"period":"3month","weight":0.1477},{"period":"6month","weight":0.9021},{"period":"1year","weight":0.734},{"period":"ytd","weight":-0.0781}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rapport Therapeutics, Inc.于2022年2月根据特拉华州法律注册成立，名称为Precision Neuroscience NewCo, Inc.，并于2022年10月更名为Rapport Therapeutics, Inc.。该公司是一家临床阶段的生物制药公司，专注于通过发现和开发用于中枢神经系统（“CNS”）疾病患者的转化小分子药物，成为精确神经科学的领导者。","exchange":"NASDAQ","name":"Rapport Therapeutics, Inc.","nameEN":"Rapport Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rapport Therapeutics, Inc.(RAPP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rapport Therapeutics, Inc.(RAPP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rapport Therapeutics, Inc.,RAPP,Rapport Therapeutics, Inc.股票,Rapport Therapeutics, Inc.股票老虎,Rapport Therapeutics, Inc.股票老虎国际,Rapport Therapeutics, Inc.行情,Rapport Therapeutics, Inc.股票行情,Rapport Therapeutics, Inc.股价,Rapport Therapeutics, Inc.股市,Rapport Therapeutics, Inc.股票价格,Rapport Therapeutics, Inc.股票交易,Rapport Therapeutics, Inc.股票购买,Rapport Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rapport Therapeutics, Inc.(RAPP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rapport Therapeutics, Inc.(RAPP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}